Allergy

Ongoing Projects

Sponsor	Protocol Code	Trial Name	Principal Investigator	Phase	Therapeutic Area	Diseases and Conditions
GSK	206867	A Phase 3, 24-week, randomized, double-blind, parallel-group Bayesian Dynamic Borrowing study comparing the efficacy, safety, tolerability and pharmacokinetics of FF/UMEC/VI with FF/VI in 12-17-year-old participants with inadequately controlled asthma on stable maintenance therapy with ICS/LABA	CANSIN SAÇKESEN (Prof.Dr.)	Phase 3	Pediatric Allergy and Immunologic Diseases	Asthma Disease